Mark D. Hjelmeland

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition

Ranjit K. Goudar, Qing Shi, Mark D. Hjelmeland et al. · Molecular Cancer Therapeutics · 2005 · 244 citations · Full text

Neuro-oncology, Mammalian Target, Glioma +13

SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility.

Mark D. Hjelmeland, Anita B. Hjelmeland, Sith Sathornsumetee et al. · PubMed · 2004 · 192 citations

Molecular Pharmacology, Neuro-oncology, Angiogenesis +12

SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility

Mark D. Hjelmeland, Anita B. Hjelmeland, Sith Sathornsumetee et al. · Molecular Cancer Therapeutics · 2004 · 172 citations · Full text

Neuro-oncology, Angiogenesis, Tgf-β Receptor +14

Bone-related Genes Expressed in Advanced Malignancies Induce Invasion and Metastasis in a Genetically Defined Human Cancer Model

Jeremy N. Rich, Qing Shi, Mark D. Hjelmeland et al. · Journal of Biological Chemistry · 2003 · 147 citations · Full text

Regulation of E2A Activities by Histone Acetyltransferases in B Lymphocyte Development

Curtis P. Bradney, Mark D. Hjelmeland, Yasuhiko Komatsu et al. · Journal of Biological Chemistry · 2003 · 81 citations · Full text